“gene-editing” Archives

in
Entry Author Date Location
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More 09/18/20 National
Lumen Bioscience Lands $16M to Engineer “Edible” Antibody Drugs 09/02/20 Seattle
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact 08/07/20 Boston
Novartis Pays $75M to Get Hands on Sangamo’s Zinc Fingers for Drug R&D 07/30/20 San Francisco
Sarepta Inks Codiak Deal to Explore Combining Exosomes, Muscle Meds 06/22/20 Boston
Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes 06/11/20 Boston
Regeneron Pays Intellia $100M to Add Hemophilia to CRISPR R&D Pact 06/01/20 New York
Viacyte Adds $27M to Move Ahead Trio of Stem Cell Diabetes Treatments 05/26/20 San Diego
Imara Reveals IPO Plan as Sickle Cell Drug Advances in the Clinic 02/18/20 Boston
Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More 02/14/20 National
FDA Clinical Hold Stops LogicBio’s Gene Editing Study Before It Starts 02/10/20 Boston
Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered 02/06/20 Boston
Emendo Eyes the Clinic for CRISPR Therapy That Makes Single-Gene Edits 01/22/20 New York
Emendo Biotherapeutics Nabs $61M for “Next-Generation CRISPR” R&D 01/15/20 New York
A Safer CRISPR? Cyrus, Broad Institute Look to Quell Concerns 12/03/19 National
Global Blood’s Sickle Cell Drug Wins FDA Approval Ahead of Schedule 11/25/19 San Francisco
Bio Roundup: Feds Sue Gilead, Biogen Eyes China, CRISPR’d Kidneys & More 11/08/19 National
eGenesis Lands $100M to Advance CRISPR-ed Pig Kidney to Human Test 11/07/19 Boston
ArsenalBio Launches With $85M for “Programmable” T Cell Therapies 10/17/19 San Francisco
Challenging CRISPR, Trucode Raises $34M for New Gene-Editing System 09/10/19 San Francisco
Vertex Bets $950M on Semma and a Stem Cell Therapy for Diabetes 09/03/19 Boston
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More 08/30/19 National
Inari Reaps $89M and Eyes Global Farm Markets for Gene-Edited Seeds 08/06/19 Boston
GlycoMimetics Sickle Cell Drug Flops as Others Creep Forward 08/05/19 New York
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More 07/12/19 National
Locana, Fueled With $55M, Looks to Develop Fixes for Faulty RNA 06/21/19 San Diego
Study: Gene Edits in CRISPR Babies Could Boost Risk of Earlier Death 06/03/19 National
Verve Has Top Cardio-Geneticist, $58.5M to Aim CRISPR at Heart Attacks 05/07/19 Boston
Bio Roundup: Nationwide’s Rise, a Surgeon’s Quest, CRISPR USA & More 04/19/19 National
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M 03/21/19 Boston
Page 1 of 6 next page »